Skip to main content
. 2023 Aug 1;10(27):2301975. doi: 10.1002/advs.202301975

Figure 3.

Figure 3

B2M is lowly expressed in Renal Cell Carcinoma and positively correlates with prognosis and PD‐L1 expression and CD8+ T cell infiltration. A) mRNA and C) protein expression of B2M between human renal cell carcinoma cell lines (786O, A498, ACHN, CAKI‐1 and OS‐RC‐2) and HK‐2 (human renal proximal convoluted tubule epithelial cell). B) mRNA and D) protein expression of Renca cell and normal kidney tissues from Balb/c mouse. E) Representative and statistical IHC results of B2M expression in RCC tumor (n = 70) samples and adjacent normal (n = 40) samples. F) Overall survival and G) Disease‐free survival of patients with high‐ or low‐B2M expression in the TCGA‐KIRC cohort using the Gepia 2.0 database (log‐rank test). H) Progression‐free survival of patients with high‐ or low‐B2M expression in the phase 3 JAVELIN Renal 101 trial (log‐rank test). I) Progression‐free survival of patients with high‐ or low‐B2M expression in our Tongji IHC samples. J) Correlation of B2M expression with tumor purity and infiltration levels of immune cells obtained from TIMER (purity‐corrected Spearman test). K) Representative and statistical IHC results of B2M (left) (n = 65), CD8 (right) (n = 55) in RCC tumors. Error bar represents mean ± SEM. Statistical significance was determined by unpaired Student's t‐test for A‐B and E and K. ns = no significant, *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001.